TSO3 Inc. (TSE:TOS) - Investment analysts at National Bank Financial issued their Q2 2017 EPS estimates for TSO3 in a research note issued on Monday. National Bank Financial analyst E. Leno forecasts that the company will earn ($0.01) per share for the quarter.
TOS has been the subject of a number of other research reports. Canaccord Genuity reaffirmed a “buy” rating and set a C$5.25 target price on shares of TSO3 in a report on Monday, June 26th. Scotiabank reaffirmed an “outperform” rating and set a C$4.50 target price on shares of TSO3 in a report on Thursday, July 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a C$4.25 target price on shares of TSO3 in a report on Wednesday, May 3rd. Five equities research analysts have rated the stock with a buy rating, TSO3 currently has a consensus rating of “Buy” and a consensus price target of C$5.00.
Shares of TSO3 (TSE:TOS) opened at 2.95 on Thursday. The stock’s 50 day moving average is $3.07 and its 200 day moving average is $3.06. The stock’s market cap is $271.49 million. TSO3 has a 52-week low of $2.20 and a 52-week high of $3.82.
In related news, Director Richard Mark Rumble sold 500,000 shares of TSO3 stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of C$3.00, for a total transaction of C$1,500,000.00.
TSO3 Company Profile
TSO3 Inc engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices. The companys principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States.
Receive News & Ratings for TSO3 Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TSO3 Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
